摘要
目的探讨比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌患者的临床疗效。方法回顾性分析2019年6月至2020年9月本院收治的82例晚期前列腺癌患者的临床资料,按照治疗方法不同分为对照组与观察组,每组41例。对照组采用比卡鲁胺治疗,观察组采用比卡鲁胺联合戈舍瑞林治疗,比较两组治疗前、治疗后1个月血清前列腺特异性抗原(PAS)、游离前列腺特异抗原(f-PSA)水平、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C-反应蛋白(CRP)水平、临床疗效。结果治疗前,两组PAS、f-PSA水平比较差异无统计学意义;治疗后1个月,两组PAS、f-PSA水平均明显低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组TNF-α、IL-6、CRP水平比较差异无统计学意义;治疗后1个月,两组TNF-α、IL-6、CRP水平均明显低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为85.37%,明显高于对照组的65.85%,差异有统计学意义(P<0.05)。结论比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌效果显著,可有效控制肿瘤生长或转移,减轻炎症反应,值得临床推广应用。
Objective To analyze the clinical efficacy of bicalutamide combined with goserelin in the treatment of patients with advanced prostate cancer.Methods The clinical data of 82 patients with advanced prostate cancer admitted to our hospital from June 2019 to September 2020 were retrospectively analyzed,and they were divided into the control group and the observation group according to different treatment protocols,with 41 cases in each group.The control group was treated with bicalutamide and the observation group was treated with bicalutamide combined with goserelin,and the serum prostate specific antigen(PAS)and free prostate specific antigen(f-PSA)levels,tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),C-reactive protein(CRP)levels before and 1 month after treatment,and clinical efficacy were compared between the two groups.Results Before treatment,there was no statistically significant difference in PAS and f-PSA levels between the two groups;1 month after treatment,the levels of PAS and f-PSA of the two groups were significantly lower than those before treatment,and the observation group was lower than in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the levels of TNF-α,IL-6 and CRP between the two groups;1 month after treatment,the levels of TNF-α,IL-6 and CRP of the two groups were significantly lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).The total effective rate of the observation group was 85.37%,which was significantly higher than 65.85%of the control group,and the difference was statistically significant(P<0.05).Conclusion The bicalutamide combined with goserelin is effective in the treatment of advanced prostate cancer,which can effectively control tumor growth or metastasis and reduce the inflammatory response,and is worthy of clinical promotion and application.
作者
张卓
张文圣
万滨
卢依刚
李勋钢
ZHANG Zhuo;ZHANG Wensheng;WAN Bin;LU Yigang;LI Xungang(Department of Urology,Jiujiang First People's Hospital,Jiujiang,Jiangxi,332000,China)
出处
《当代医学》
2023年第8期82-84,共3页
Contemporary Medicine
关键词
比卡鲁胺
戈舍瑞林
晚期前列腺癌
Bicalutamide
Goserelin
Advanced prostate cancer
Clinical effects
